ArticlePNAS nexus2025
Prediction of hallucinogen persisting perception disorder and thought disturbance symptoms following psychedelic use.
Article in PNAS nexus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Psychedelic Safety and Clinical Outcomes Across Exposure Patterns: A Structured Narrative Review.Life (Basel, Switzerland) · 2026Review
- Safety and Mental Health Outcomes of Oregon State-Regulated Psilocybin Services.JAMA network open · 2026Article
- Ten practical suggestions for setting up a psychedelic study.Journal of psychopharmacology (Oxford, England) · 2026Article
- Characterising the clinical associations of hallucinogen persisting perception disorder: a retrospective cohort study.Translational psychiatry · 2026Article
- The science of psychedelic medicine.Nature medicine · 2026Review
- Considerations and cautions for the integration of psilocybin into routine clinical care: a consensus statement from the US National Network of Depression Centers' Task Group on Psychedelics and Related Compounds.EClinicalMedicine · 2025Review
- Psychedelics for Alcohol Use Disorder: A Narrative Review with Candidate Mechanisms of Action.CNS drugs · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Interest in using psychedelic drugs to treat psychiatric disorders is growing rapidly. While modern controlled clinical trials show a favorable safety and efficacy profile, it remains unclear if the risk of side effects would increase with broader use in more heterogeneous populations. To address this, we investigated the frequency and baseline predictors of delusional ideation, magical thinking, and "hallucinogen persisting perception disorder" (HPPD)-related symptoms following psychedelic use in a self-selected naturalistic sample. Using a prospective cohort study, symptoms were assessed in (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.